samedan logo
 
 
 
spacer
home > ebr > spring 2008 > a peek into europe
PUBLICATIONS
European Biopharmaceutical Review

A Peek into Europe

Robin Bhattacherjee of CV Therapeutics Europe offers key considerations for US biopharmaceutical companies looking to branch out into Europe

Europe is not a single entity. It sounds so obvious but this is the single and fundamentally most important point for any company to understand, whether US-based or elsewhere, when considering whether to establish themselves in Europe. The regulatory and licensing process conducted by the European Medicines Agency (still referred to as the EMEA) continues to move Europe towards total regulatory harmonisation. A product approved via the centralised procedure will have a single licence for all 27 member states. National licences for a product for which the intention is to promote it across the whole of Europe are now unheard of, and this can lull one into a false sense that Europe is unified in terms of healthcare provision. However, once a product is licenced, harmonisation ends. After that, each country in which you want to market your product has its own healthcare system, authorities and institutes, and pricing and reimbursement system. In short, it is a highly complex region and any new company considering an expansion into Europe will require a detailed strategic approach.

WHY EUROPE?

For a US company, Europe is the obvious region to consider for expansion after their home continent. As a territory, it is second only to the US in terms of market value, and typically accounts for approximately 30 per cent of global pharmaceutical sales in any particular therapeutic area. In 2005, total pharmaceutical sales in the region were approximately $170 billion, with seven per cent growth (1).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Robin Bhattacherjee is Executive Director at CV Therapeutics Europe. Robin is involved in the general management of CVT Europe and is responsible for developing and implementing the commercial and scientific communication strategy for CVT in Europe. He also plays a major role in business development activities. Robin joined the company from Sanofi-Synthélabo, where he was Head of Cardiovascular Marketing, responsible for managing the cardiovascular portfolio in the UK, and also sat on the Irbesartan Global Strategy Team. Prior to this, from 1986 to 2002, Robin held a variety of positions at Bayer including Marketing Manager and National Sales Manager. Most recently he was the Cardiovascular Marketing Director in Bayer’s Global Strategic Marketing Group. During his career, Robin has been involved in a number of product launches both in the UK and Europe. Robin holds an honours degree in Biological Sciences from the University of London.
spacer
Robin Bhattacherjee
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera reinforces its value proposition with a refreshing visual identity

At Nemera, we have been successfully providing high quality drug delivery device solutions to our customers and patients for years. We design and manufacture devices with the ultimate goal to improve patient outcomes and experience.
More info >>

White Papers

PhlexEarchive: The Right Solution for Electronic Archiving of TMF Content

Phlexglobal Ltd

Many sponsor organizations have already recognized the value of moving from paper to electronic Trial Master Files (eTMFs). But few sponsors have taken a more holistic approach to the TMF lifecycle and looked at the entire process from study start-up through archiving of the TMF in electronic format, also known as e-archiving. The recurring value of managing, tracking, maintaining and accessing electronic files should not stop at the point of archiving. All of the challenges of managing an active paper TMF carry through to a paper archive. All of the benefits of an electronic TMF also carry through to the electronic archive. As companies look to move their compliance assets to secure, long-term storage, it is important to consider ongoing compliance requirements, security, accessibility, efficiency and costs of archiving TMF content in a digital format.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement